Tempus xT – pro
Tempus xT-DNA is presented as a targeted panel of 648 genes enriched for clinically relevant genes and most commonly mutated cancer driver genes with additional genes of emerging clinical significance focused on immediately actionable mutations. However, 648 genes cannot possibly be all actionable. IN addition, it uses a different technology than commonly available NGS. Tempus analyzes the DNA, RNA, and specific proteins of cancer cells to understand the patient’s disease at the molecular level so it can identify personalized treatment options designed to specifically target their unique cancer. As such, it requires a significantly higher burden of proof before being widely accepted. Proudman et al concluded that replacing 20% of usual testing with Tempus xT CGP was associated with a small incremental testing cost and can identify meaningfully more actionable alterations.
David Proudman et al, Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use. Journal of Medical Economics Volume 25, 2022 – Issue 1
Beaubier N, Tell R, Lau D, et al. Clinical validation of the tempus xT next-generation targeted oncology sequencing assay. Oncotarget. 2019;10(24):2384–2396.
Pruneri G, De Braud F, Sapino A, et al. Next-Generation sequencing in clinical practice: is it a cost-saving alternative to a single-gene testing approach? Pharmacoecon Open. 2021;5(2):285–298.
Schwartzberg L, Kim ES, Liu D, Schrag D. Precision Oncology: Who, How, What, When, and When Not? Am Soc Clin Oncol Educ Book. 2017;37:160-169.